Myeloma Novel Drug Discovery Ver 1.2
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitute of Cancer Research, United Kingdom
About this trial
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Eligibility criteria
Qualifiers
Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
Participants aged 18 years of age or above
Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
Disqualifiers
Participants unable to provide consent
Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Trial design
Treatments tested in this trial
- Observational study - sample collection only.
Treatment groups
250 Participants
are divided into 1 treatment groupSponsors and collaborators
Institute of Cancer Research, United Kingdom
Lead sponsor
Royal Marsden NHS Foundation Trust
Collaborator
Source ClinicalTrials.gov